Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06395415

Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults

Electronic Nicotine Delivery Systems (ENDS) use remains prevalent among young adults, and many have high interest in quitting, yet research on effective intervention is lacking. A mobile health (mHealth) intervention that translates effective smoking cessation materials and pharmacotherapy may be a promising avenue for intervention. The initial phase of the proposed study uses a pilot study to evaluate a novel mHealth intervention for young adult ENDS and dual product (ENDS and combustible cigarette) users.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–26 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Chicago BREATHE Laboratory

Chicago, Illinois, 60637, United States

Location status: Recruiting

Location contact

Emma Dr. Brett

CONTACT

[email protected]

773-834-5341

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-26 years old, ability to understand the English language, willing and able to provide informed consent
  • Current ENDS user (at least 4 out of 7 days per week of use for the past one month); for focus groups, at least half of participants will report current cigarette smoking (at least 1 cigarette per day on at least 1 day per week in the past month)
  • Report interest in quitting or reducing ENDS (at least 6/10 scale in interest of quitting or reducing
  • Does not currently (in past one year) meet criteria for major psychiatric disorder including severe alcohol or substance use disorder (excluding tobacco use disorder), schizophrenia, bipolar disorder, and obsessive compulsive disorder
  • For women, not currently pregnant, planning to become pregnant, or breastfeeding due to lack of information on ENDS use and possible harms from NRT during pregnancy
  • Not currently using smoking cessation medication (i.e., Varenicline, Bupropion
  • No history of adverse reactions to nicotine replacement therapy

Exclusion criteria

  • Does not own a mobile phone or is unwilling to receive text messages to their device
  • No interest in quitting or reducing use of ENDS
  • Uses electronic cigarettes less than 4 days per week in the past month
  • Reports past-year serious psychiatric illness, including severe alcohol or substance use disorder (excluding tobacco use disorder), schizophrenia, bipolar disorder, and obsessive compulsive disorder
  • Is currently using smoking cessation medication including Varenicline or Bupropion
  • Are a female who is currently pregnant or nursing or planning to become pregnant within the next 6 months

Treatment and study plan

EQUIP

Behavioral

The intervention is delivered directly to participants' mobile phones using the Insight® platform, which allows for the implementation of assessments and interventions. Insight has been used in prior mHealth studies and allows for the delivery of tailored content based on parameters, such as intervention stage. The intervention has two stages: 1) Motivational enhancement (weeks 1-2) and 2) Skills and information (weeks 3-6). The first stage of messages will utilize personalized feedback and motivational interviewing prompts, while the second stage will provide health information on ENDS and skills, such as deep breathing. Content is tailored to motivation level (low/medium or high) and dual use status.

Standard Care

Behavioral

Those in the standard advice group will be given offered a sample of NRT, instruction on its use, and will be encouraged to use in conjunction with standard web-based resources on ENDS and cessation over the course of a ten minute walk-through with study staff.

Primary outcomes

  1. ENDS cessation

    Time frame: post-treatment (6 weeks) and at 6-week follow-up (week 12).

    ENDS cessation will be measured using a modified Timeline Followback Interview using 7-day point prevalence abstinence with study staff and then confirmed via a mailed saliva cotinine test.

Secondary outcomes

  1. ENDS use

    Time frame: post-treatment (6 weeks) and at 6-week follow-up (week 12).

    Frequency of ENDS use as determined by Timeline Followback Interview with study staff will be measured as a secondary outcome.

Study contacts

Contact information is provided by the study sponsor or research team.

Emma Brett, PhD

CONTACT

[email protected]

773-834-5341

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Registry information

Acronym: EQUIP

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 2, 2024
Registry last updated
Apr 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.